<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1552">
  <stage>Registered</stage>
  <submitdate>3/11/1994</submitdate>
  <approvaldate>10/02/2010</approvaldate>
  <actrnumber>ACTRN12610000134022</actrnumber>
  <trial_identification>
    <studytitle>An international multi-centre study of tamoxifen vs placebo in women at increased risk of breast cancer.</studytitle>
    <scientifictitle>A multicentre trial of Tamoxifen to prevent breast cancer in women at increased risk of breast cancer.</scientifictitle>
    <utrn />
    <trialacronym>ANZ92P1/ IBIS-I</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR63</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prevention of Breast cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm A: Tamoxifen 20 mg/day tablet orally for 5 years</interventions>
    <comparator>Arm B: Placebo (unknown constituents) tablet/day orally for 5 years</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Development of histologically confirmed breast cancer (both invasive and non-invasive i.e. including Ductal Carcinoma Insitu (DCIS)).</outcome>
      <timepoint>Interim analysis of the data will be by blinded analysis at 6 monthly intervals up to 5 years from baseline</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Breast cancer mortality.</outcome>
      <timepoint>Interim analysis of the data submitted on case record forms will be analysed to assess breast cancer mortality at 6 monthly intervals up to 5 years from baseline</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>All cause and cause-specific mortality.</outcome>
      <timepoint>Interim analysis of the data submitted on case record forms will be analysed to assess breast cancer mortality at 6 monthly intervals up to 5 years from baseline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Occurrence of and mortality from myocardial infarction.</outcome>
      <timepoint>Blood pressure  and cholesterol assays will be taken at year 1 and year 5 and interim analysis of the data submitted on case record forms will be analysed to assess breast cancer mortality at 6 monthly intervals up to 5 years from baseline</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Women must satisfy at least one of the entry criteria listed below.
A) Age 45-70 with at least one of the following:
1. Breast cancer in mother, sister or daughter diagnosed under the age of 50
2. Mother, sister or daughter with cancer in both breasts at any age
3. Any two first or second degree relatives (blood relatives) with breast cancer
4. Having no children, and with a mother or sister with breast cancer at any age
5. Having had a benign biopsy with proliferative disase and a mother, sister or daughter who developed breast cancer at any age
6. Having had a biopsy with lobular carcinoma in situ 
7. Having had a benign biopsy with atypical ductal or lobular hyperplasia 
8. "Other" equivalent risk to the above (to be confirmed by the Study Chairman

B) Age 40-44 with at least one of the following:
9. Any two first or second degree relatives (blood relatives) with breast cancer under the age of 50
10. Mother, sister, or daughter with breast cancer in both breasts under the age of 50
11. Having no children, and a mother or sister with breast cancer under the age of 40
12. Having had a benign biopsy with proliferative disease and a mother, sister or daughter with breast cancer under the age of 40
13. Having had a biospy with lobular carcinoma in situ
14. Having had a benign biopsy with atypical ductal or lobular hyperplaisa
15. "Other" equivalent risk to the above (to be confirmed by the study chairman)

C) Age 35-39 with at least one of the following:
16. Two relatives, mother, sister or daughter with breast cancer under the age of 50
17. Mother, sister or daughter with breast cancer in both breasts under the age of 40
18. Having had a biopsy with lobular carcinoma in situ
19. "Other" equivalent risk to the above (to be confirmed by the study chairman)</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>a) Women with previous deep vein thrombosis or pulmonary embolus are excluded from the study
b) Women must not use hormonal contraception during the trial
c) Pregnant or at pregnacy risk
d) Life expectany less than 10 years
e) Currently being treated with anticoagulants
f) Previous cancer</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Telephone the National Health &amp; Medical Research Council Clinical Trials Centre and the next randomised trial number for the centre will be issued which will become the woman's trial number and will be used to identify her 6 month supply of tablets.  All subsequent supplies of tablets will be based on this number.</concealment>
    <sequence>Simple randomisation by using a randomisation table created by computer software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>The clinicians and trial participants are blinded in this study.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>7/04/1992</anticipatedstartdate>
    <actualstartdate>1/12/1992</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/03/2001</actualenddate>
    <samplesize>7000</samplesize>
    <actualsamplesize>7154</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,WA,VIC</recruitmentstate>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Queen Mary University of London</primarysponsorname>
    <primarysponsoraddress>Queen Mary, University of London
Mile End Road
London 
E1 4NS</primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Imperial Cancer Research Fund</fundingname>
      <fundingaddress>Cancer Research UK
P.O. Box 123
Lincoln's Inn Fields
London WC2A 3PX</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cancer Research Campaign</fundingname>
      <fundingaddress>Cancer Research UK
P.O. Box 123
Lincoln's Inn Fields
London WC2A 3PX</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cancer Research UK</fundingname>
      <fundingaddress>Cancer Research UK
P.O. Box 123
Lincoln's Inn Fields
London WC2A 3PX</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health Medical Research Council grant</fundingname>
      <fundingaddress>National Health Medical Research Council
Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Breast Cancer Trials</sponsorname>
      <sponsoraddress>PO Box 283
The Junction NSW 2291</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A study to evaluate the reduction in incidence of, and mortality from, breast cancer associated with taking tamoxifen daily for five years</summary>
    <trialwebsite>https://www.ibis-trials.org/index.php/thetrials/ibistrials/ibis-1</trialwebsite>
    <publication>Cuzick J. Continuation of the International Breast Cancer Intervention Study (IBIS). Eur J Cancer 1998; 34(11):1647-1648.

Cuzick J. Future possibilities in the prevention of breast cancer: breast cancer prevention trials. Breast Cancer Res Treat 2000; 2:258-263.

Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, Cuzick J. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 2001; 19(7):1885-1892.

Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T, for IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS I): a randomised prevention trial. Lancet 2002; 360:817-824.
Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast cancer prevention trials. Lancet 2003; 361:296-300.

Eckermann SD, Martin AJ, Stockler MR, Simes RJ. The benefits and costs of tamoxifen for breast cancer prevention. ANZ J Public Health 2003; 27(1):34-40.

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Th√ºrlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21(17):3357-3365.

Cuzick J, Warwick J, Pinney E, Warren RML, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004; 96(8):621-628.
Cuzick J, Forbes J, Howell A. Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2006; 98(9):643.

Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol 2006; 24(24):3991-3996.
Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, for the International Breast Cancer Intervention Study (IBIS) I Investigators. Long-term results of tamoxifen prophylaxis for breast cancer - 96 month follow-up of the randomized IBIS I trial. J Natl Cancer Inst 2007; 99(4):272-282.

Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RML Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: A nested case-control study J Natl Cancer Inst 2011; 103(9):744-52.

Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer Breast Cancer Research and Treatment 2012; 134(2):727-734.

Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL, for the SERM Chemoprevention of Breast Cancer Overview Group Selective oestrogen receptor modulators in the prevention of breast cancer: an updated meta-analysis of individual participant data. The Lancet 2013; 381(9880):1827-1834.

Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF, on behalf of the IBIS-I Investigators. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncology 2015; 16:67-75.
Smith SG, Sestak I, Howell A, Forbes J, Cuzick J. Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). Journal of Clinical Oncology. 2017; 35(23):2666-2673.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>Breast Cancer Trials formerly known as the Australia &amp; New Zealand Breast Cancer Trials Group.</publicnotes>
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/12/1992</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bendigo Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Canberra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Central Sydney IBIS Centre, (comprising Dubbo Base Hospital, Rachel Forster Hospital, Royal Prince Alfred Hospital)</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch IBIS Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Flinders Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Breast Clinic</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Queensland IBIS Centre, (comprising Wesley Breast Clinic and Wesley Medical Centre)</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Sydney</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Tasmanian IBIS Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Waikato Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Janine Lombard</name>
      <address>Staff Specialist Medical Oncology / Conjoint Lecturer, University of Newcastle
Calvary Mater Newcastle
Department of Medical Oncology
Locked Bag 7
HUNTER REGION MAIL CENTRE NSW 2310</address>
      <phone> +61 (02) 4014-3584</phone>
      <fax />
      <email>janine.lombard@calvarymater.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Corinna Beckmore</name>
      <address>BCT
PO Box 283
The Junction NSW 2291</address>
      <phone>+61 2 4925 5235</phone>
      <fax>+61 2 4925 3068</fax>
      <email>enquiries@bctrials.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Janine Lombard</name>
      <address>Staff Specialist Medical Oncology / Conjoint Lecturer, University of Newcastle
Calvary Mater Newcastle
Department of Medical Oncology
Locked Bag 7
HUNTER REGION MAIL CENTRE NSW 2310</address>
      <phone>+61 (02) 4014-3584</phone>
      <fax />
      <email>janine.lombard@calvarymater.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>